Research Paper Volume 16, Issue 6 pp 5618—5633
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy
Figure 1. Effect of stromal and immune scores on survival of patients with TERTp-mutant gliomas. (A) Kaplan-Meier survival analysis of patients in the high and low immune score groups. (B) Kaplan-Meier survival analysis of patients in the high and low stromal score groups. (C) Volcano plot showing differential gene expression for the high and low immune groups. (D) Heat map depicting differential gene expression between TERTp-mutant gliomas in the high and low immune groups. (E) Volcano plot showing differential gene expression for TERTp-mutant gliomas in the high and low immune groups. (F) Heat map showing DEGs between TERTp-mutant gliomas in the high and low stromal groups. (G) Venn diagram of upregulated genes in the high stromal and immune groups. (H) Venn diagram of downregulated genes in the high stromal and immune groups. (I) PPI network constructed using 71 overlapping DEGs while removing isolated genes. Genes in the PPI network was set as candidate hub genes. (J) Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of candidate hub genes. (K) GO-Biological process (BP) analysis of candidate hub genes. (L) GO-Cellular component (CC) analysis of candidate hub genes. (M) GO-Molecular function (MF) analysis of candidate hub genes.